A
ANIK icon

AlphaQuest’s Anika Therapeutics ANIK Stock Holding History

AlphaQuest’s Portfolio ANIK Stock Details ANIK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-1,607
Closed -$15.4K – 131
2025
Q4 		$15.4K Hold
1,607
– – ﹤0.01% 2124
2025
Q3 		$15.1K Buy
+1,607
New +$15.3K ﹤0.01% 2127
2025
Q2 		– Sell
-1,607
Closed -$24.2K – 2045
2025
Q1 		$24.2K Buy
1,607
+298
+23% +$4.96K ﹤0.01% 1677
2024
Q4 		$21.5K Sell
1,309
-5,595
-81% -$110K ﹤0.01% 1415
2024
Q3 		$171K Buy
6,904
+3,705
+116% +$96.1K 0.02% 1128
2024
Q2 		$81K Sell
3,199
-1,276
-29% -$33.1K 0.01% 985
2024
Q1 		$114K Sell
4,475
-2,420
-35% -$58.6K 0.02% 790
2023
Q4 		$156K Buy
+6,895
New +$143K 0.03% 677

Other funds holding ANIK

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
CM
Capital Management Glen Allen, Virginia $666M AUM 17.17% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

AlphaQuest's ANIK Position: Q1 2026 in Review

AlphaQuest sold out of Anika Therapeutics (ANIK) in Q1 2026, closing a stake of 1,607 shares — an estimated $15.4K sold.

AlphaQuest first reported a position in ANIK in Q4 2023 and held it in 8 quarters. The position peaked at $171K in Q3 2024. 130 funds tracked by Wall St. Rank hold ANIK as of Q1 2026.

  • AlphaQuest reported no remaining Anika Therapeutics position as of Q1 2026 after selling out during the quarter.
  • AlphaQuest sold 1,607 Anika Therapeutics shares in Q1 2026, an estimated $15.4K.
  • AlphaQuest first reported a position in Anika Therapeutics in Q4 2023 and held it in 8 quarters.
  • AlphaQuest's Anika Therapeutics position peaked at $171K in Q3 2024.
  • 130 funds tracked by Wall St. Rank held Anika Therapeutics as of Q1 2026.

Based on AlphaQuest's 13F filing for Q1 2026.